Massmedica

Massmedica S.A. Appoints New Supervisory Board Members for 2026-2027 Term

Massmedica S.A., a leading distributor of high-tech medical implants and regenerative medicine products, has announced the appointment of its new Supervisory Board members for the 2026-2027 term. The appointments were finalized during the company’s Ordinary General Meeting held on June 30, 2026. The newly elected members include:

• Jan Brykczyński – Chairman of the Supervisory Board, with extensive experience in direct sales networks and leadership roles in global companies.
• Joanna Różalska – Member of the Supervisory Board, with a background in international relations and public relations, and significant experience in the aesthetic medicine industry.
• Prof. Dr. Hab. N. Med. Jan Skowroński – Member of the Supervisory Board, a renowned orthopedic surgeon and academic with decades of experience in orthopedics and traumatology.
• Hubert Młodzianowski – Member of the Supervisory Board, specializing in business process software for the financial sector and currently collaborating with Sollers Consulting.
• Wojciech Kaszycki – Member of the Supervisory Board, with extensive expertise in capital markets, fintech, gaming, and medtech industries.

The term for the newly appointed Supervisory Board members will conclude on June 30, 2027, coinciding with the approval of the company’s financial statements for the fiscal year 2027. The appointees bring a wealth of experience from diverse fields, including medicine, technology, and business, which is expected to further strengthen Massmedica’s strategic direction and market position.

Relevance to Massmedica S.A.: The appointment of a highly qualified Supervisory Board aligns with Massmedica S.A.’s commitment to maintaining its leadership in the distribution of advanced medical implants and regenerative medicine products, ensuring strong governance and strategic growth in the healthcare sector.

Massmedica S.A. Completes Prototype of URSA Minor Surgical Robot

Massmedica S.A. has announced the successful completion of the prototype for its Universal Robotic Surgical Assistant (URSA) project, named URSA Minor. Developed by its subsidiary, Massmedica Technologie Sp. z o.o., the prototype is now ready for testing. The company is focusing on further development and optimization of the system’s software, including surgical planning algorithms, navigation, imaging data integration, and user interface refinement. Additionally, Massmedica is awaiting the delivery of a final robotic arm with enhanced precision to replace the current test arm.

The next phase of the project involves clinical-like testing, scheduled for April 2026, at an anatomy facility using unpreserved human specimens. These tests aim to validate the system’s accuracy, operational ergonomics, and readiness for certification and commercialization. The company has emphasized the revenue potential of the URSA project and its strategic importance for Massmedica’s growth and technological advancement.

Relevance: This development aligns with Massmedica S.A.’s focus on high-tech medical solutions, particularly in the field of reconstructive medicine, and underscores its commitment to innovation in surgical robotics.

Massmedica S.A. Secures Record-Breaking Tender for Endoprostheses and Surgical Robot Rental

Massmedica S.A. has announced its successful bid for a significant tender to supply endoprostheses and rent the Omnibotics surgical robot to a Polish public hospital. The total contract value amounts to PLN 7,489,260 net, with deliveries scheduled over the next two years. This tender represents the largest order in the company's history and accounts for nearly 10% of its order portfolio for the upcoming two years, which now exceeds PLN 78,000,000. The company highlighted the strategic importance of this contract, citing its potential to significantly impact future revenues and financial performance. Details of the agreement will be disclosed in a separate communication.

Relevance: This achievement aligns with Massmedica S.A.'s focus on high-tech medical solutions, including surgical robots and advanced implants, reinforcing its position as a leader in reconstructive medicine and innovative healthcare technologies.